Buckland's interim results were published at 6pm on Friday - not a time when you would expect a recovering company (as this one seems to be) to report. Its statement also lacked a balance sheet, which should be forthcoming reasonably soon (apparently net assets totalled £1.1m at the end of June). There are a few issues of concern besides this, notably £210,000 of extra exceptional costs on the liquidation of its French subsidiaries that are not explained fulsomely. But the fact is the group is back in profit, after years of losses associated with those French operations. Pre-tax profits before exceptional provisions totalled £149,000 in the 6-month period to June, on £2.3m of sales. House broker Seymour Pierce's John Beddoe says final results 'should be in line' with his note of 30 July, in which he recommended the shares as a 'Strong Buy', with £339,000 of pre-exceptional profits pencilled in. As for the strangely-timed and incomplete results, Beddoe adds: 'There is nothing untoward there.' On such a low prospective p/e, with 0.24p of EPS this year, his recommendation looks reasonably sound.
Market cap: £900,000
PE Forecast: 2.6
Share price: 0.62p
More breaking news stories.
More extended feature articles.
And a depth of analysis you
can't find anywhere else.
Advertisement
VCT Report 2010 uncovers the money available
for investment in every single VCT, helping you get one step ahead in the race to attract funding for your unquoted, AIM-listed or PLUS-quoted
company.
Order VCT Report 2010 today using this online form
A comprehensive overview of cash shells on AIM and PLUS, companies that have become a significant feature on the market landscape. For more information and to order, click here or contact our marketing team on 020 7250 7056.
Informative features and research on fast-growing companies, small-cap and growth stocks, penny shares, stock market tips and share recommendations, directors' dealings, company news and analysis, new issues and upcoming IPOs.
A full year's subscription to What Investment magazine for £19.95, a whopping 58% off. Get the latest news, features and expert advice on ISAs, Investment Trusts and Funds, SIPPS, Investing for Children and much much
more. Find out more here.
is the definitive and most up-to-date guide to completing your self-assessment tax return, making sure that you get it right and on time, and showing how you can save tax. For more information and to order, click here or contact our marketing team on 020 7250 7056.
The new, fully updated AIM Guide is now available to buy for only £49.95 (saving you £30).
A 'must-have' for any serious investor or professional interested in the market for young, fast-growing companies. Order your copy today Hurry, as offer ends soon!
Small-cap and growth company share recommendations on AIM- and PLUS-listed companies. Latest analysts' stock tips and advice on which are the best shares to buy on London's junior stock markets.
Advertisement
Delcam, the international seller of CAD/CAM software to the engineering, aerospace and healthcare sectors among others, is a cash-generative small-cap seeing recovery in its markets.
Bombed-out biotech play Antisoma is hoping two of its drugs will lead to good fortune after experiencing disaster with lung cancer treatment ASA404.
London pub operator The Capital Pub Company is seeing continuing sales growth on the back of a surprisingly resilient market.